A novel chemotherapy and radiation regimen significantly improves outlook for patients with early-stage Hodgkin's disease

November 13, 2001

A short course of chemotherapy followed by radiation significantly improves time to disease progression and minimizes toxicity in patients with early-stage Hodgkin's disease, a study by the Southwest Oncology Group reports.

The study - the largest randomized trial of early-stage Hodgkin's disease conducted in the U.S. in two decades - evaluated whether chemotherapy should be part of the treatment regimen for patients with early-stage Hodgkin's disease. Earlier studies utilizing other chemotherapy combinations followed by radiation also demonstrated improved progression-free survival rates; however, patients experienced excessive toxicities.

The study also determined that staging laparotomy - a previously common abdominal surgery used to diagnose the stage of Hodgkin's disease - could be avoided. Instead of undergoing staging laparotomy, patients in the trial were staged clinically, by examining tumor size, lymph node involvement, and where the disease has spread.

In the 10-year, phase III trial, 348 patients who had not undergone staging laparotomy were randomized to receive either a combined treatment of three cycles of doxorubicin and vinblastine followed by radiation, or radiation alone. Radiation therapy levels were the same for patients in both arms.

Of the patients who received the combined treatment, the three-year failure free survival rate was 94 percent compared to 81 percent of patients who received only radiation therapy. Patients who achieved failure free survival did not experience a recurrence of their disease or develop any other treatment-related complications during the three-year follow-up period. Because of the significant results, the study was stopped at the second interim analysis after nine years.

"Patients receiving this novel chemotherapy regimen followed by radiation achieved a marked improvement in failure free survival rates compared with patients treated with radiation therapy alone," said Oliver Press, M.D., a Professor of Medicine in the Division of Medical Oncology at the University of Washington. "This study also showed that staging laparotomy was not necessary to obtain excellent failure free survival rates for patients with early-stage Hodgkin's disease."

Ten patients experienced disease progression in the combined treatment group compared to 34 on the radiation therapy group, and only one treatment-related death occurred on each arm. Because highly toxic chemotherapy drugs were not used, patients generally experienced manageable side effects.

During the last three to four years, combined treatment regimens of short course chemotherapy followed by radiation such as the one used in this trial have become the standard of care for patients with early-stage Hodgkin's disease. Today, most physicians use even smaller radiation fields than were used in this study.
-end-
"Phase III Randomized Intergroup Trial of Subtotal Lymphoid Irradiation Versus Doxorubicin, Vinblastine, and Subtotal Lymphoid Irradiation for Stage I to IIA Hodgkin's Disease." Oliver W. Press, MD, et al.; Division of Medical Oncology, University of Washington, Seattle , WA. Vol 19, No 22 (November 15) 2001, pp: 4238-4244.

The Journal of Clinical Oncology is the semi-monthly peer-reviewed journal of the American Society of Clinical Oncology (ASCO), the world's leading professional society representing physicians who treat people with cancer.

ATTRIBUTION TO THE JOURNAL OF CLINICAL ONCOLOGY IS REQUESTED IN ALL NEWS COVERAGE. For the Full Text of Any JCO Article, Contact (212) 584-5025 or (703) 299-1016.

The JCO News Digest is also distributed via email. Please let us know if you would like to be added to our email distribution list.

American Society of Clinical Oncology

Related Chemotherapy Articles from Brightsurf:

Chemotherapy is used to treat less than 25% of people with localized sarcoma
UCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone.

Starved cancer cells became more sensitive to chemotherapy
By preventing sugar uptake, researchers succeeded in increasing the cancer cells' sensitivity to chemotherapeutic treatment.

Vitamin D could help mitigate chemotherapy side effects
New findings by University of South Australia researchers reveal that Vitamin D could potentially mitigate chemotherapy-induced gastrointestinal mucositis and provide relief to cancer patients.

Less chemotherapy may have more benefit in rectal cancer
GI Cancers Symposium: Colorado study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose.

Male fertility after chemotherapy: New questions raised
Professor Delb├Ęs, who specializes in reproductive toxicology, conducted a pilot study in collaboration with oncologists and fertility specialists from the McGill University Health Centre (MUHC) on a cohort of 13 patients, all survivors of pediatric leukemia and lymphoma.

'Combo' nanoplatforms for chemotherapy
In a paper to be published in the forthcoming issue in NANO, researchers from Harbin Institute of Technology, China have systematically discussed the recent progresses, current challenges and future perspectives of smart graphene-based nanoplatforms for synergistic tumor therapy and bio-imaging.

Nanotechnology improves chemotherapy delivery
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.

Novel anti-cancer nanomedicine for efficient chemotherapy
Researchers have developed a new anti-cancer nanomedicine for targeted cancer chemotherapy.

Ending needless chemotherapy for breast cancer
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment.

A homing beacon for chemotherapy drugs
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy.

Read More: Chemotherapy News and Chemotherapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.